Path: ...!weretis.net!feeder8.news.weretis.net!usenet.goja.nl.eu.org!3.eu.feeder.erje.net!feeder.erje.net!feeder2.feed.ams11.usenet.farm!feed.usenet.farm!peer03.ams4!peer.am4.highwinds-media.com!news.highwinds-media.com!fx10.ams4.POSTED!not-for-mail
MIME-Version: 1.0
User-Agent: Mozilla Thunderbird
Newsgroups: fr.bio.medecine
Content-Language: fr
From: Paul Aubrin <paul.aubrin@invalid.org>
Subject: =?UTF-8?Q?L=27homologation_d=27un_vaccin_combin=C3=A9_grippe-covid_?=
 =?UTF-8?Q?suspendue?=
Content-Type: text/plain; charset=UTF-8; format=flowed
Content-Transfer-Encoding: 8bit
Lines: 8
Message-ID: <CY3QO.978916$XGr1.929339@fx10.ams4>
X-Complaints-To: abuse@eweka.nl
NNTP-Posting-Date: Thu, 17 Oct 2024 08:32:34 UTC
Organization: Eweka Internet Services
Date: Thu, 17 Oct 2024 10:32:34 +0200
X-Received-Bytes: 1063
Bytes: 1328

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-places-trials-two-novavax-vaccines-hold-2024-10-16/
Par Bhanvi Satija 16 octobre 2024 20:19 GMT+2

La Food and Drug Administration (FDA) a suspendu un essai du vaccin 
antigrippal COVID de Novavax (NVAX.O), et de ses vaccins antigrippaux 
dédiés après qu'un participant ayant pris la combinaison a signalé des 
lésions nerveuses, a déclaré la société mercredi.